DORMAN STUART 4
4 · IDEAYA Biosciences, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
IDEAYA (IDYA) CCO Stuart Dorman Receives 155,000-Share Award
What Happened
Stuart Dorman, Chief Commercial Officer of IDEAYA Biosciences (IDYA), was granted 155,000 derivative shares (award) on January 30, 2026. The award was reported as acquired at $0.00, meaning no cash was paid at grant—this is a compensation award (e.g., RSUs or similar equity-based award) rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-01-30; Form 4 filed: 2026-02-02.
- Grant type: Derivative award (code A); 155,000 shares acquired at $0.00 (no cash consideration).
- Vesting (per footnote): 25% vests on the first anniversary measured from January 1, 2026 (the Vesting Commencement Date), then 1/48th of total shares vest monthly thereafter; 100% vests on the fourth anniversary.
- Shares owned after the transaction: not specified in the provided filing summary.
- No indication of a sale, cash exercise, gift, or tax-withholding event in this report.
Context
This is a standard equity compensation grant to an executive and does not represent an open-market buy or sell. Such awards typically align executive incentives with long-term shareholder value but do not immediately change public float or signal a near-term trading intent. The filing date (Feb 2, 2026) closely follows the transaction date (Jan 30, 2026), consistent with routine insider reporting timelines.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-01-30+155,000→ 155,000 totalExercise: $32.19Exp: 2036-01-30→ Common Stock (155,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.